These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18417272)

  • 1. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Speakman MJ
    Eur Urol; 2008 Jul; 54(1):178-9. PubMed ID: 18417272
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Bastian PJ
    Eur Urol; 2008 Jul; 54(1):179-80. PubMed ID: 18417273
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Ficarra V; Novara G
    Eur Urol; 2008 Jul; 54(1):178. PubMed ID: 18417274
    [No Abstract]   [Full Text] [Related]  

  • 4. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Gres AA; Arustamov DL
    Eur Urol; 2008 Jul; 54(1):170-7. PubMed ID: 18417275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
    Drewa T; Chlosta P
    Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
    Siejka A; Schally AV; Block NL; Barabutis N
    BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
    Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
    Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation.
    Tiboni GM; Palumbo P; Leonzio E; Gabriele E; Verna I; Giampietro F
    Gynecol Endocrinol; 2011 Nov; 27(11):885-9. PubMed ID: 21500992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol.
    Griesinger G; Dawson A; Schultze-Mosgau A; Finas D; Diedrich K; Felberbaum R
    Fertil Steril; 2006 Mar; 85(3):791-3. PubMed ID: 16500366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study.
    Engel JB; Audebert A; Frydman R; Zivny J; Diedrich K
    Eur J Obstet Gynecol Reprod Biol; 2007 Oct; 134(2):225-32. PubMed ID: 16930803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the LHRH antagonist Cetrorelix on the brain function in mice.
    Telegdy G; Tanaka M; Schally AV
    Neuropeptides; 2009 Jun; 43(3):229-34. PubMed ID: 19375162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the gonadotropin-releasing hormone antagonist cetrorelix in the early postimplantation period on rat pregnancy.
    Tug N; Uslu U; Cumbul A; Eyuboglu S; Cam C; Karateke A; Yilmaz B
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):166-70. PubMed ID: 21242023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.